Submission declined on 16 May 2024 by
Grabup (
talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
Submission declined on 10 May 2024 by
Samoht27 (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
Samoht27 2 months ago.
|
Submission declined on 29 December 2023 by
Timtrent (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
Timtrent 7 months ago.
|
Submission declined on 9 December 2023 by
ToadetteEdit (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
ToadetteEdit 7 months ago.
|
Submission declined on 1 December 2023 by
Stuartyeates (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
Stuartyeates 7 months ago.
|
Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology. [1] The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.
NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia [2]. As of 2023, NTX-250 is in the preclinical stage of development.
Submission declined on 16 May 2024 by
Grabup (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
Submission declined on 10 May 2024 by
Samoht27 (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
Samoht27 2 months ago.
|
Submission declined on 29 December 2023 by
Timtrent (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
Timtrent 7 months ago.
|
Submission declined on 9 December 2023 by
ToadetteEdit (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
ToadetteEdit 7 months ago.
|
Submission declined on 1 December 2023 by
Stuartyeates (
talk). This draft's references do not show that the subject
qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by
Stuartyeates 7 months ago.
|
Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology. [1] The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer.
NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia [2]. As of 2023, NTX-250 is in the preclinical stage of development.
-
in-depth (not just brief mentions about the subject or routine announcements)
-
reliable
-
secondary
-
strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.